Showing 501 - 520 results of 100,885 for search '(( 59 mean decrease ) OR ( 5 ((wt decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.27s Refine Results
  1. 501
  2. 502

    Flowchart of patients. by Seydou Goro (17847203)

    Published 2024
    “…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”
  3. 503

    Baseline characteristics of patients. by Seydou Goro (17847203)

    Published 2024
    “…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”
  4. 504

    Image 5_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

    Published 2024
    “…</p>Methods<p>Mice were inoculated with 10<sup>7</sup> CFU of the eubiotic bacteria Lactobacillus crispatus, the dysbiotic bacteria G. vaginalis, or PBS as a negative control every 48 h for ten days. On day ten, mice were inoculated with 10<sup>5</sup> PFU WT HSV-2 333 and survival, pathology, and viral titers were assessed. …”
  5. 505
  6. 506
  7. 507
  8. 508

    Image5_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  9. 509
  10. 510
  11. 511
  12. 512
  13. 513
  14. 514
  15. 515
  16. 516
  17. 517
  18. 518
  19. 519
  20. 520